Conditions: Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Keywords: NHL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

Detailed description:
This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab. Chemotherapy cycles will be given as outlined below every 35-days and will continue until two cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression, or a maximum of 8 cycles.

Arms:
arm 1: Velcade 375 mg/m\^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.

Interventions: intervention 1: VELCADE® intervention 2: Rituximab intervention 3: Cyclophosphamide intervention 4: Decadron
Intervention descriptions: intervention 1: 1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22. intervention 2: 375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle. intervention 3: 400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle. intervention 4: 40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23

Protocol document: